NCT06581432 2026-03-17
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Boehringer Ingelheim
Phase 2 Recruiting
Clinical Trials
24 trialsNCT07446855 2026-03-03
PARTHENON
AstraZeneca
Phase 1/2 Not yet recruiting
NCT07160725 2026-02-17
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT06725758 2026-01-15
TEADES
Orion Corporation, Orion Pharma
Phase 1/2 Recruiting
NCT02360345 2024-09-26
ONX-0801
Royal Marsden NHS Foundation Trust
Phase 1 Completed
NCT01948297 2020-09-09
Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations
Debiopharm International SA
Phase 1 Terminated
NCT04179071 2020-07-07
A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine
AstraZeneca
Phase 1 Completed
NCT03702036 2020-04-13
Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
GlaxoSmithKline
No longer available
NCT02264418 2020-01-18
KIDES-203
Orion Corporation, Orion Pharma
Phase 1 Completed
NCT03415100 2018-08-01
Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours
The Third Affiliated Hospital of Guangzhou Medical University
Phase 1 Unknown
NCT03315091 2018-04-30
Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT01998607 2018-01-09
Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw
Amgen
Completed
NCT00732420 2017-11-13
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00136578 2017-09-25
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00743067 2017-07-26
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00695448 2017-07-25
Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma
GlaxoSmithKline
Phase 1 Terminated
NCT00742261 2017-07-07
A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT02215850 2016-05-17
Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours
Welichem Biotech Inc.
Phase 1 Completed
NCT01209091 2016-02-03
Utility and Work Productivity Data for Economic Evaluation of Breast Cancer Therapies in the Netherlands and Sweden
GlaxoSmithKline
Completed
NCT02056392 2015-11-09
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
AstraZeneca
Phase 1 Completed
NCT01931761 2015-06-30
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers
AstraZeneca
Phase 1 Completed
NCT02093728 2015-06-30
To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
AstraZeneca
Phase 1 Completed
NCT01974349 2014-08-13
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
AstraZeneca
Phase 1 Completed
NCT00497679 2009-05-14
AZD1152 in Patients With Advanced Solid Malignancies-Study 3
AstraZeneca
Phase 1 Terminated